A Founder-led Fund for Innovative Science

This is a once-in-a-generation convergence of biology and computation!

The advances in AI bring a massive and unprecedented level of opportunities and acceleration across the various verticals in life science (eg. BioPharma, MedTech, Diagnostic, Digital Health).

As an example, AI is transforming into the $1.8T+ global drug R&D market.1 While drug development takes on average 10yrs, 90% of drug candidates fail during the R&D and clinical process. However, by improving target selection, prediction, and validation, AI has the potential to fundamentally reshape productivity across the entire R&D, and clinical stages of drug development.

Beyond therapeutics, AI is driving disruption across a $1T+ healthcare ecosystem, spanning across verticals including MedTech, diagnostics, and digital health.2 Within this landscape, AI-enabled diagnostics and digital health are among the fastest-growing segments, fueled by the increasing importance of data, automation, and real-time decision-making.3

Accelerating the entire life science sector growth:

• Overall, AI is accelerating innovation by providing new alternatives optimizing the accuracy of patient care and treatment delivery.

• AI in life sciences is growing at an average of ~38% CAGR across prevention, diagnosis, monitoring and drug discovery.

• Increasing M&A appetite and activity from larger players to acquire trailblazing and agile early-stage companies.

1. Grand View Research (Market Analysis Report 2024) Biotechnology Market (2024-2030)

2- PWC (Report 2025) Industry is our edge- From breaking point to breakthrough: the $1 trillion opportunity to reinvent healthcare

3- BCG (Report 2024) Health Care Industry- The Future of Digital Health 2024

A global venture capital fund investing in AI-powered life sciences companies transforming how diseases are prevented, detected, and treated.

With a tandem fund + lab, Linearis is pioneering and supporting discoveries through direct investments in innovative AI-healthcare companies.

A) What is our investment thesis?
The future of healthcare will be predictive, personalized, and AI-driven. Linearis invests in life science companies generating impact on a global scale for patients. Its portfolio companies transform therapeutic, MedTech, diagnostic and digital health through the combination of innovation and augmented transformative power of AI.

The portfolio companies enable:

• Early diagnostics

• Disease prediction and prevention

• Drug discovery acceleration

• Patient monitoring

B) What is a “Venture + Lab” model? 
We support portfolio companies across the full lifecycle:

• Deal sourcing

• Leading or co-leading financing rounds

• Accelerating syndicated through our network of international investors

• Performing due diligence

• Continued hands-on coaching

• Lab/technical platform for experimental validation, data generation and AI modeling

• Scaling and partnerships

• Governance support and Board presence 

• Social and networking events

 Our tandem venture + lab model:

• Improves product/service market fit

• Opportunity to validate the science

• Accelerate speed to market

• Elevating probability of success

• Optimizing potential exits potential M&A deals

C) Who is behind Linearis Ventures?
Our management team has been in the tranches, and partners with selected key world-class AI and metabolomic advisors.

• Successful Investors: Over 35 investments in early-stage companies as angels or VCs, limited partners in several funds in life sciences and other industries giving us a solid network of investors springboarding our syndications efforts. Our investor and operator background  give us in-depth experience with successful exits and M&A partnerships (buy and sell sides).

• Experienced Operators: AI entrepreneurs and serial founders who raised money, lived on 4 continents, managed $200M USD in operating budget, navigated pivots, growth and international scaling. Involved in life-cycle management, product roadmaps, and global launches of 5 blockbusters across 3 BioPharma NASDAQ-listed companies. Over the years, coached more than 100 companies through various incubators/accelerators and across Creative Destruction Lab (CDL) streams.

• Company growth: Successfully scaled life sciences and IA teams across geographies in Canada, the US, Europe, and Asia.

• World Renown Advisors: Collaborate with world experts in AI advising various listed-companies, and governments as well as lead innovator in genomics and metabolomics.

We don’t just invest — we generate and validate biological data, accelerating both science and returns. 

Our operator-led fund provides more than capital with in-depth AI and life science expertise, we work with founders while offering them a rich international network, a unique platform combining a lab infrastructure with a wide range of AI and analysis support services.

This creates a feedback loop between biology and AI, improving both investment decisions and company outcomes. 

A) What do we strive for and our DNA?
The purpose of our distinct tandem ‘’Venture + Lab’’ entity differentiates us, and is part of our core DNA as we strive to elevate the ecosystem through our aspirations, partnerships and investments.

Our Vision: Shaping the future of healthcare by harnessing the convergence of AI and life science to enable partnerships and improve outcomes.

Our Mission: We invest in founders and accelerate innovation in life science through AI to transform healthcare.

Our Values:

• Build trust in the quality of our data

• Create accessible technologies

• Innovate for our partners

• Maintain integrity and excellence in our work

• Have passion for improving people’s health

B) What stage do you invest in?
We invest in AI-life sciences late Seed to Series B companies, targeting companies with high-impact and growth potential.

C) What kind of companies do you invest in?

• AI-driven drug discovery platforms and/or companies

• MedTech

• Biomarker discovery

• Diagnostics

• Digital health and patient monitoring

• Multi-omics platforms

• Predictive medicine and disease modeling

D) What is your geographic focus?
We invest where the best science and AI talent converge, we are globally active with focus in:

• North America

• Europe (including partnerships with IA institutes-eg. Sorbonne AI)

• Asia-Pacific (including collaborations with renowned universities in Japan)

A) How we reduce risk: Our business and operation tandem model amplifie risk mitigation through data and validation:

• Biological validation via Linearis Labs

• AI-driven analysis of disease signatures

• Early identification of promising candidates

• Access to real-world datasets and biobanks

B) What traction do you already have?

• Since our inception in Q4 2024, we’ve invested across our core verticals: AI drug discovery, therapeutics, and MedTech (see selected investments).

• Syndicated deals and preparing announcements in collaboration with other investors

• Demonstrated early portfolio success with rapid value creation (eg. Jan 2026, Noetik announced a $50M USD contract with GSK)

• Developed strategic partnerships with key life sciences companies and industry collaborators

• Strong syndication with leading VCs in life science

• Our tandem model received backing from major AI and life sciences ecosystems

With Fund 1, we are building a growing long-term leading AI-life sciences investment platform by combining:

• Venture capital

• Operator and investor experience

• AI excellence

• Biological data infrastructure

Aim to:

• Create breakthrough companies

• Accelerate medical innovation

• Generate impact and superior investor returns